← All Compounds
Mechanism Nonapeptide known for modulating sleep architecture and promoting delta-wave sleep. Acts on multiple targets including GABA-A receptors, serotonergic pathways, and cortisol regulation without causing sedation. Half-Life Approximately 15-25 minutes Route subcutaneous Frequency Once daily (before sleep)
FDA Category Research peptide (removed from FDA Category 2) Reclassification removed-from-cat2 Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
DSIP (Emideltide)
Removed from Cat 2
Neuropeptide · Research peptide (multiple suppliers)
Nonapeptide researched for sleep architecture modulation and stress-related cortisol regulation. Not FDA-approved for any indication.
About
Clinical Dosing
100-300 mcgonce daily (before sleep)
Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Protocol
Source: Kovalzon & Strekalova, Journal of Neurochemistry, 2006
| Dose | Duration | Draw (2 mg vial in 2mL) | Notes |
|---|---|---|---|
| 100 mcg | Maintenance | 0.10 mL (10 units) | Standard research dose before sleep |
Available Vial Sizes
2 mg
2 mg vial
5 mg
5 mg vial
Citations
- [1]Delta Sleep-Inducing Peptide (DSIP): A Still Unresolved Riddle. Journal of Neurochemistry, 97(2), 303-309. Link(Reviewed: 2026-04-16)